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Uveal tract melanoma (UVM) is the most common primary
intraocular malignancy in adults, accounting for about
5–10% of all the melanomas [1]. Male: female ratio is 1.3:1.
The disease is rare in children and young adults, the incidence
rises gradually with age peaking at about 70 years [2]. In the
famous Collaborative Ocular Melanoma Study (COMS), the
risk of distant metastasis at 10 years of diagnosis was 34%
[1]. Also, after the diagnosis of metastasis, the median time
to death was six months [3]. Several risk factors for melanoma
have been identified including fair skin, having blond or red
hair, light-colored eyes, extensive freckling, history of one or
more severe, blistering sunburns, excessive ultraviolet (UV)
light exposure, living closer to the equator or at a higher eleva-
tion, having >50 mol or atypical moles (dysplastic nevi), a
family history of melanoma and immunosuppression [4].
The uveal tract comprises of iris, ciliary body, and choroid,
and UVM can involve one or more structures. Ciliary body
and choroidal melanomas constitute about 95% of all UVM.
Iris is reported to harboring melanoma in only 5% of cases.
Another distinguishing peculiarity of iris melanoma is that it
very rarely metastasises [5].
Melanoma is named so because of its origin from melano-
cytes. However, the amount of pigment in the lesion varies giv-
ing rise to a spectrum of color usually dark brown and black.
There have been reports of amelanotic melanoma in various
parts of the body [6]. Recent studies suggest a relationship
between tumor pigmentation and risk of growth and metasta-
sis, with a better prognosis for lightly pigmented or amelanotic
lesions [7]. A typical choroidal melanoma is dark brown andelevated subretinal mass. In 1931, Callender documented dis-
tinctive cell types in the gamut of cells composing UVM.
The modified Callender classification is based on cell size,
shape, cytoplasmic features, loss of cohesion, nuclear and
nucleolar characteristics. Three categories according to this
system include spindle cell melanomas (30% of intraocular
tumors), mixed-cell melanomas (65%), when fewer than half
of the cells in the sections examined are composed of epithe-
lioid cells, and epithelioid cell melanomas, when greater than
half of the tumor sections are composed of epithelioid cells,
accounting for 5% of UVM [8]. The pathologist’s designation
of a particular cell type involves subjective judgment.
UVM usually remains confined to the globe. Larger tumors
may develop extra-scleral extension, with approximately 15%
of cases demonstrating extra-scleral extension. Other pathways
of extraocular spread include the optic nerve and the lumen of
vortex veins [9]. Since there are no lymphatic vessels in the
globe, UVM can only spread hematogenously. Distant metas-
tasis is identified in almost 50% of patients after 25 years of
diagnosis [10]. Liver is the most common (89%) site of distant
metastasis [11].
Diagnosis
Clinical examination
The diagnosis of UVM is frequently clinical, with accuracy
reaching 99.7% in specialized centers [12].
Ultrasonography
The combined use of A- and B-mode techniques is vital in
confirming the clinical diagnosis of choroidal melanoma with
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choroidal melanoma shows medium to low internal echoes
with smooth attenuation along with vascular pulsations within
the tumor. On B-scan, there are three classic features of
choroidal melanoma: an acoustically silent zone within the
tumor, choroidal excavation and shadowing in the orbit [14].
Besides, ultrasonography acts as a valuable tool for follow
up in patients with conservative treatment.
Photography
Fluorescein angiography is highly useful in differentiating mel-
anoma from hemorrhage or hemangioma. In patients with
melanoma, it usually causes irregular hyperfluorescence in
the early phase while staining of the tumor is observed in the
late phase [15]. However, the orange pigmentation in the reti-
nal pigment epithelium typically blocks the early hyper-
fluorescence. Larger melanomas may show a patchy pattern
of early hypofluorescence and hyperfluorescence followed by
late intense staining. Some choroidal melanomas demonstrate
intrinsic vascularization, visible throughout the angiogram.
The angiographic sign, called the ‘‘double circulation pattern,”
refers to simultaneous fluorescence of retinal and choroidal cir-
culation within the tumor. When it occurs, it is fairly distinc-
tive of choroidal melanomas [15]. Also, very important roles
of colored fundus photographs are the accurate assessment
and follow up of the basal dimension of the lesion primarily
and post treatment.
The patterns of indocyanine green videoangiography
(ICGV) are variable, depending primarily on the degree of
tumor pigmentation, thickness, and vascularity. In the early
frames of ICGV, hypofluorescence can be observed in all cases
[14]. Intrinsic choroidal vasculature is discernible in some
cases. In the late phase of ICGV, the patterns include hyper-
fluorescence and three-ring [15].
Fine-needle aspiration biopsy (FNAB)
Obtaining the pathology report prior to starting definitive
treatment is not routinely recommended. However, when the
clinical diagnosis is uncertain, then diagnostic biopsy can be
considered balancing the potential risks of the procedure.
FNAB can be performed either with a direct transscleral or
transvitreal approach. Prognostic biopsy is also considered,
if the patient desires for it. The current practice now in the
most advanced centers in the world dealing with uveal melano-
mas is to obtain FNAB for cytogenetic studies of the tumor at
the time of treatment (plaque or enucleation) and in the few
cases where there is doubt about the clinical diagnosis.
Other diagnostic tools
Ocular coherence tomography (OCT) is a useful adjunct to dif-
ferentiate large choroidal nevi from melanomas [14]. Choroi-
dal nevi tend to have clearly defined margins and to be flat
or slightly elevated, and they remain stable in size. In contrast,
choroidal melanomas are more likely to show signs of activity
such as relatively indiscrete margins, irregular or oblong con-
figuration, overlying subretinal fluid and orange pigment,
and abruptly elevated edges.
Magnetic resonance imaging (MRI) can be used to provide
intraocular enhancement of the lesion that may help in predict-
ing the degree of malignancy and for monitoring the response
to treatment.Metastatic workup
Since melanoma has a high risk of distant metastasis, thorough
physical examination, imaging studies and biochemical tests
are necessary as the baseline work up. Abdominal ultrasonog-
raphy, chest X-ray, and computed tomography (CT) of the
head are useful in the staging work up. The results of COMS
study indicate that liver function tests, followed by diagnostic
tests, are highly specific and have high predictive values but the
sensitivity remains low [16]. Some institutions employ whole-
body positron emission tomography/CT as a part of staging
work up [17]. The presence of tyrosinase or MelanA/MART1
transcripts have been reported to be an independent prognostic
factor for the development of metastases [18,19].
Staging
Staging is an important tool in the prognostication of the
patient but it should not delay the primary management of
the tumor. Patients should have whole body staging (chest,
abdomen and pelvis) with CT scan or PET-CT. Brain imaging
and bone scan are required only in presence of related symp-
toms. In patients with liver metastasis, in order to assess for
resectability, contrast enhanced MRI with diffusion weight
imaging is required. For extra hepatic disease, contrast-
enhanced CT scan is advisable for accurate staging. COMS
staging is widely used, it takes into account tumor thickness
and basal diameter [20]. The results of various randomized
clinical studies are based on COMS staging. The current
TNM staging by the American Joint Committee on Cancer
(AJCC) draws somewhat different boundary lines for small,
medium, and large tumors [21].
Management
The therapy selected for choroidal melanoma should be indi-
vidualized and is dependent on various factors, such as
patient’s age, tumor size and location, general health, and sta-
tus of the fellow eye. However, there is no proven survival
advantage between any of the offered modalities.
Small choroidal melanoma
In the management of suspected small choroidal melanomas,
the most important issue is to decide when to start definite
therapy. The authors recommend each case to be individual-
ized. The useful therapies include transpupillary thermal ther-
apy (TTT) and radiation therapy [22]. Besides, plaque
radiotherapy can also be used by an experienced clinician to
treat small uveal melanomas [23]. There exists a controversy
about treatment of certain uveal melanomas. For example,
in the diagnosis of ‘‘small” AJCC T1 uveal melanomas, the
American Brachytherapy Society (ABS)-Ophthalmic Oncol-
ogy Task Force (OOTF) recommends that in the absence of
thickness P2 mm, subretinal exudative fluid and superficial
orange pigment lipofuscin tumors; patients could be offered
the alternative of ‘‘observation” for the evidence of change
(within 6 months) typically for documented growth prior to
intervention. This is particularly applicable for tumors near
the fovea and optic nerve, or monocular patients where treat-
ment is likely to cause radiation related vision morbidity.
Table 1 Table showing treatment options according to size of ocular melanoma.
Feature Small choroidal melanoma Medium choroidal melanoma Large choroidal
melanoma
Criteria for
size
Apical height 1–2.5 mm 2.5–10 mm >10 mm
Largest basal
diameter
5 mm 5–16 mm >16 mm
Treatment options  Laser photocoagulation
 Transpupillary thermal therapy
(TTT)
 Plaque radiotherapy
 Proton beam therapy
 Stereotactic radio surgery
(SRS)
 Customized plaque
RT
 Enucleation
68 A. Kapoor et al.Laser photocoagulation therapy
Xenon arc photocoagulation was replaced by argon laser pho-
tocoagulation, which showed fewer complications but less
tumor control [24]. The major limitations of laser therapy
include poor tissue penetration and the requirement for multi-
ple treatment sessions. Hence, laser therapy has been super-
seded by TTT.
Transpupillary thermal therapy
Infrared light (diode laser, 810 mm) is used as heat to induce
necrosis in tumor tissues. The tumor recurrence rate was
10% at 3 years, with visual acuity worse than 20/200 in 32%
of cases in the report by Shields et al. [23]. The ideal candidate
for TTT is small, heavily pigmented melanoma less than 3 mm
thick with minimal or no subretinal fluid, located in the extra-
macular region but not touching the optic disk. Delayed recur-
rence and extrascleral extension are the important drawbacks
of TTT. This treatment can be used as an adjunct to plaque
radiotherapy [22].
Medium-sized choroidal melanoma
Plaque radiotherapy results in equivalent survival as that of
enucleation for the management of medium sized choroidal
melanoma [25]. Local sclero-chorioretinal resection can reserve
vision with good cosmesis [26]. However, it is associated with
early complications leading to preference for radiotherapy
for this indication (see Table 1).
Radiation therapy
Radiotherapy is presently the most widely used treatment for
medium-sized posterior uveal melanoma [27]. The armamen-
tarium of radiation therapy for melanoma includes plaque
brachytherapy, external-beam radiation using photons or
charged particles (protons and helium ions) and stereotactic
radiosurgery with modified linear accelerators and multisource
cobalt units [28–30]. A comparison of these techniques is given
in Table 2.
Episcleral plaque radiation therapy
ABS-OOTF recommends that brachytherapy exclusion criteria
include: tumors with gross (T4e or >5 mm) extraocular exten-
sion, blind painful eyes and those with no light perception
vision [31].The custom-designed plaque is temporarily sutured to the
sclera overlying the tumor, usually under retrobulbar or gen-
eral anesthesia. Operative localization of the plaque placement
is guided by translumination, ophthalmoscopic observation, or
ultrasonography. The plaque remains in place for 2–5 days,
depending on the type and activity of the radioactive source,
and it is then removed under similar operative conditions.
Iodine 125 (125I) is the most commonly used radioisotope
[32]. Ruthenium 106 (106Ru) is frequently used in Europe;
other isotopes include cobalt 60 (60Co) and palladium 103
(103Pd) [33]. Isotopes with lower photon and electron radiation
(125I, 106Ru, 103Pd) are more easily shielded to reduce the expo-
sure to adjacent normal tissues in the patient, with a concomi-
tant reduction in exposure risk to medical personnel. The
radioisotope 103Pd has dosimetric advantages based on its
lower photon energy as compared to 125I. Clinical trials of
103Pd have been favorable [34].Charged-particle beam therapy
Charged-particle beams (protons or helium ions) are available
at a relatively few sites around the world. These have dosimet-
ric advantage in terms of delivery of a high dose of radiation to
highly precise targets. A retrospective review of 218 patients
treated with helium ion irradiation, with a minimum follow-
up period of 10 years, demonstrated 95% local control [28].
Twenty-two percent of patients required enucleation, most
often for anterior segment complications. Impairment of visual
acuity was noted for tumors P6 mm thick and located within
3 mm of the optic nerve and fovea [32].
A large single-institution retrospective comparison of pro-
ton beam-treated patients with those undergoing enucleation
showed no apparent difference in long-term survival: an
update on 1922 patients with a median follow-up of 5.2 years
showed 5- and 10-year local failure rates of 3.2% and 4.3%,
respectively, following proton beam radiation (PBR) [29].
Approximately half of the failures were marginal, suggesting
possible treatment planning or delivery errors. Another sur-
vival study on the relative rates of metastatic death, cancer
death, and all-cause mortality between enucleation and
PBR revealed a statistically significant survival benefit in
the PBR group in the first two years of treatment. However,
by the sixth year the survival benefit was not maintained. In
general, it appears that tumor control with charged-particle
and plaque radiotherapy, as well as radiation complications,
is similar.
One early main complication after PBR is intraocular
inflammation. Lumbroso et al. found 28% of patients
developed ocular inflammation [35]. It is correlated with larger
Table 2 Table showing review of all the available treatment options for ocular melanoma.
Treatment Used for Outcomes Complications Comments
Radiotherapy
Brachytherapy
ruthenium106
Iodine125
Small/medium /large uveal
melanoma*
<20 mm in basal diameter
Good local
tumor control
Loss of vision tumor
recurrence
Dose and position of plaque can be adjusted to
limit the loss of vision
Proton Beam
radiotherapy
Medium to large uveal
melanoma which cannot be
treated with brachytherapy or
resection
Good local
tumor control
Loss of vision Loss of
the eye from
neovascular glaucoma
tumor recurrence
Not available in all ocular oncology units
Stereotactic
radiosurgery
Juxta-papillary uveal
melanoma; patients unsuitable
for ruthenium plaque or unfit
for surgery
Good local
tumor control
Loss of vision Radiation
related complications
tumor recurrence
Lower availability
Phototherapy
Transpupillary
thermotherapy
Local recurrence and of
adjuvant therapy of uveal
melanoma
Improves local
tumor control
Loss of vision
Extraocular tumor
recurrence
Very occasionally used by some centers for
small melanoma nasal to the optic disk. When
considering preservation of vision, for example
in a one eyed patient; as it avoids radiotherapy
complications.
However, it is no longer recommended
routinely as a sole primary treatment.
Photodynamic
therapy
Small melanoma Uncertain Tumor recurrence Avoids radiotherapy complications
New treatment option not widely used for
uveal melanoma. This is an experimental
treatment.
Surgery
Exoresection
+/ plaque
Medium to large melanoma
with a narrow basal diameter
Variable Retinal detachment
Loss of vision
Loss of the eye tumor
recurrence
Risk of orbital
dissemination of tumor
Rarely performed
Always performed with brachytherapy to
reduce the risk of recurrence
Endoresection
+/
radiotherapy
Medium-sized uveal
melanoma
Toxic tumor syndrome post
PBR
Variable Transient intraocular
haemorrhage; rarely
tumor seeding
Only performed in limited centers
Enucleation Large uveal melanoma
Melanoma associated with
NVG +/ extensive retinal
detachment
100% local
tumor control
if completely
excised
Socket related
complications Orbital
recurrence
Cosmetic results are reasonably good with an
orbital implant and artificial eye
Exenteration Large extra-ocular extension
after uveal melanoma
100% local
tumor control
if completely
excised
Orbital recurrence Rarely performed
Table 3 Modalities for surveillance of uveal melanoma: advantages and disadvantages.
Modality Advantages Disadvantages
Liver function tests High NPV, inexpensive, accessible Low sensitivity, poor PPV
Chest X-ray Noninvasive, inexpensive, accessible Low sensitivity, low yield
Abdominal
Ultrasonography
Noninvasive, inexpensive, accessible Limited by body habitus, operator dependent
Computed
Tomography
High sensitivity, whole body imaging, moderate/
high resolution
Low PPV, false positives, radiation exposure
PET/CT Whole body imaging Lower specificity, expensive, inaccessible, poor resolution, UM
moderately FDG
avid, radiation exposure, false positives
Magnetic Resonance
Imaging
High resolution/sensitivity, good detection for
lesions >1 cm
Limited by body habitus, metallic implant and claustrophobia,
false positives
NPV, negative predictive value; PPV, positive predictive value; UM, uveal melanoma; FDG, fludeoxyglucose (18F).
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70 A. Kapoor et al.initial tumors (tumor height and irradiation of a large volume
of the eye) and may be related to an exudative retinal detach-
ment and tumor necrosis, both of which in turn are thought to
lead to an associated release of cytokines and neovascular
glaucoma (termed, ‘toxic tumor syndrome’).
Large choroidal melanoma
Enucleation is generally reserved now for advanced melano-
mas greater than 15 mm in diameter and more than 10 mm
thick. It is also employed with the resection of a long portion
of optic nerve in cases where there is optic nerve invasion. Pla-
que radiotherapy can also be customized to treat large uveal
melanomas [34]. Patients with large tumors or with tumors
at peripapillary and macular locations have a poorer visual
outcome and lower local control that must be taken into
account in the patient decision-making process.
Orbital exenteration
Orbital exenteration was previously done in every case of
extrascleral extension. However, it does not significantly
improve survival for patients with mild to moderate extrascle-
ral extension [36]. In cases of massive orbital extension occur-
ring with a blind, painful eye, primary orbital exenteration
appears justified.
Pre-enucleation external beam radiation
Pre-enucleation radiotherapy for uveal melanoma was thought
to possibly reduce enucleation-induced systemic metastasis.
However, a randomized trial by COMS involving 1000
patients failed to show any survival advantage by pre-
enucleation radiation [37].
Management of patients with metastatic disease
The prime route of spread of ocular melanoma is hematoge-
nous, with liver being the most common site of distant metas-
tasis. In the COMS study, the sites of metastases at death were
liver in 91%, lung in 26%, bone in 18%, skin in 12%, and
lymph nodes in 11% of patients [20]. Hepatic metastases are
recognized as a poor prognostic marker for response to treat-
ment and survival. The overall 1-year survival after the devel-
opment of metastasis is only 13%, and median survival
estimates range from 2 to 9 months [21]. Surgical resection of
liver metastases not indicated as melanoma is a systemic dis-
ease at this stage. The ABS-OOTF recommends that the pres-
ence of metastatic disease from uveal melanoma is not an
absolute contraindication for brachytherapy. For example,
there exist ocular situations where brachytherapy may limit
or prevent vision loss from tumor associated retinal detach-
ment or when tumor growth will soon cause secondary angle
closure glaucoma. In addition, brachytherapy of the primary
tumor may allow the patient to enter systemic treatment trial
where a small proportion will survive. Systemic chemotherapy
has been ineffective, with response rates reported to be 1% or
less in most series, and cytokine therapy with interleukin-2 and
interferon-c have been similarly ineffective [38]. A variety of
regional treatment modalities, such as hepatic arterialchemotherapy, hepatic artery chemoembolization, regional
immunotherapy, isolated hepatic perfusion, and percutaneous
hepatic perfusion, are being used to control tumor progression
in the liver. Most reports show at best a modest response rate,
suggesting that selected patients with uveal melanoma may
occasionally benefit from aggressive treatment. In the absence
of a proven standard of care or clinical trial, many patients
with metastatic uveal melanoma currently receive best sup-
portive care or dacarbazine chemotherapy for 4–6 cycles.
Unlike skin melanoma, mutations in the BRAF gene are
exceptionally rare and thus for these patients BRAF-directed
therapies are unhelpful [39].
The anti-CTLA4 agent, ipilimumab has National Institute
for Health and Care Excellence (NICE) approval for previ-
ously treated advanced (unresectable or metastatic) melanoma
based upon clinical trials in skin melanoma. There are two
independent, favorable prognostic factors: fewer than ten
metastases at screening and the absence of ciliary body
involvement. The increasing understanding of the underlying
biology of uveal melanoma has led to the identification of a
number of novel and promising therapeutic strategies that
warrant investigation. Currently, an increasing number of
novel agents are under evaluation in well-designed prospective
and uveal-specific phase II clinical trials. A randomized phase
II study in 98 patients compared selumetinib versus temozolo-
mide has reported improved response rate and doubling of
PFS (15.9 versus 7 weeks) [40]. Pembrolizumab (MK-3475) is
a drug that targets the programed cell death 1 (PD-1) receptor
meant to treat metastatic melanoma [41]. As per an abstract
presented in recent ASCO meeting, treatment with pem-
brolizumab appears to be a viable option for patients with
metastatic uveal melanoma [42].Prognostic and predictive factors
The identification of prognostic factors is of limited value due
to the lack of effective treatment to prevent or delay metasta-
sis, or for metastatic disease itself. The patients treated with
plaque brachytherapy, proton beam radiotherapy or stereotac-
tic radiotherapy should be monitored for tumor regression
intensively over the first two years following treatment [43].
Further follow up is decided on the basis of response of the
tumor to brachytherapy and the radiotherapy complications
experienced.
Clinical prognostic factors
Anatomic site
Ciliary body melanoma has the poorest prognosis as compared
to choroidal or iris melanoma. Tumors actually arising in the
ciliary body are aggressive and have a 5-year mortality of 53%,
compared with 14% for choroidal-based melanomas [43].
Invasion of the optic nerve worsens the prognosis [44]. If a
tumor extends outside the eye, the 10-year mortality rate is
75%.
Tumor growth pattern
About 5% of posterior uveal melanomas grow in a diffuse pat-
tern. Twenty-four percent of patients with diffuse melanoma
have metastases at 5 years and 36% at 10 years [45].
Management of uveal tract melanoma 71Tumor size
Tumor size is extremely useful as tumor measurements are
available at the time of diagnosis, thus it can help in prognos-
tication of the patient [46].
Histopathological prognostic factors
Microvascular patterns
The presence of microvascular networks, defined as at least
three back-to-back closed loops, is a feature strongly associ-
ated with the development of metastatic disease [43].
Cell type
Cell type, as determined by the Callender classification, is pre-
dictive of outcome. It was found that 95% of patients with
spindle A tumors, 85% of those with spindle B tumors, 60%
of those with mixed tumors, and 83% with epithelioid tumors
were alive 5 years after enucleation [8].
Tumor-infiltrating lymphocytes and macrophages
Tumor-infiltrating macrophages (CD68+ cells) are an inde-
pendent prognostic factor for survival [47]. Approximately
5–12% of uveal melanomas contain lymphocytes, and these
are thought to represent an important component of the host’s
immune response to the tumor. Both T- and B-lymphocyte
infiltrations were associated with higher mortality.
Cytogenetic and molecular prognostic factors
Uveal melanomas characterized by monosomy 3 have aggres-
sive tumor behavior, such as greater tumor size, ciliary body
involvement, the presence of epithelioid cells, and closed loop
vasculogenic mimicry [48]. Conversely, metastasis in the
absence of monosomy 3 is rare. Also important in uveal mel-
anomas are abnormalities involving chromosomes 8, 6, 9,
and 1 [49].
Rb protein is expressed in virtually all melanomas, indicat-
ing a lack of Rb gene mutation [49]. Gain of chromosome 8q
correlates strongly with the expression of DDEF1, a gene
located at 8q24. DDEF1 may act as an oncogene in uveal mel-
anoma, and it may be a useful diagnostic marker [50]. Also, the
expression of the Nijmegen breakage syndrome (NBS1) gene
was a strong predictor of uveal melanoma survival [49].
Surveillance options for patients with uveal melanoma following
definitive management
About 50% of melanoma patients who have attained local
control ultimately develop distant metastases. Still there is no
consensus about the role of surveillance for the detection of
metastatic disease in these patients. Since there is no survival
benefit from the early detection of asymptomatic disease, there
is controversy over the value of routine surveillance. Table 3
depicts the various modalities for the surveillance of uveal mel-
anoma along with their advantages and disadvantages.
Conclusions
Uveal melanoma is a complex malignancy that requires a high
degree of expertise in its management. To select the best pos-
sible strategy, the management plan should be individualized.Despite all measures, uveal melanoma has a high propensity
for distant failure.Conflicts of interest
Nil.Source of funding
Nil.
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